Format

Send to

Choose Destination
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.

Author information

1
Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.
2
Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.

KEYWORDS:

antimycobacterial; in vitro; tuberculosis

PMID:
26224770
DOI:
10.1093/cid/civ460
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center